N@N

ImmunoGen, Inc. Announces Webcast of Presentation at the 28th Annual J.P. Morgan Healthcare Conference

^{Published on 2010-01-06 13:05:08 - Market Wire}
 

WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc ]. (Nasdaq: IMGN) is scheduled to present at the 28^th Annual J.P. Morgan Healthcare Conference at 9:30 am PST on January 14, 2010. The Conference is being held at the Westin St. Francis hotel in San Francisco, CA. ImmunoGen's presentation will be webcast live and can be accessed through the "Investor Information" section of our website, [ www.immunogen.com ]. An archive of the webcast will be available at the same location until January 21, 2010.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at [ www.immunogen.com ].